NeurodermatitisNCT07206680
Effect of Extracorporeal Shockwave Therapy on Pruritus in Neurodermatitis Patients
A study testing Shockwave therapy and Emollients & corticosteroids in people with Neurodermatitis, run by Cairo University at 1 site in Egypt.
Trial summary
The purpose of this study is to evaluate the therapeutic effect of shockwave therapy on reducing pruritus in neurodermatitis patients. Read more about this study
- Who is it for?
- Ages 55 to 75 years
- Conditions the study is for
- Neurodermatitis
- What is being tested?
- Shockwave therapy and Emollients & corticosteroids
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 34 participants
- Where
- 1 siteEgypt
- Study dates
- 15 Dec 2024to 25 Oct 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 55 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age range between 55:75 years.
- Male and female patients will participate in the study.
- All patients have neurodermatitis.
- All patients will be received the same approach of medication and nursing care.
- All patients enrolled in the study will have their informed consent.
Who cannot join
- Patients diagnosed with cancer.
- Pregnant woman.
- active infection.
- Patients with any systemic diseases that may interfere with the objectives of the study.
- Cardiac pacemakers or other implantable devices.
- Current anticoagulation use.
- Any other cause of itching
Trial locations and contacts
1 site in 1 country.
About this study
The purpose of this study is to evaluate the therapeutic effect of shockwave therapy on reducing pruritus in neurodermatitis patients.
Read the detailed description
Based on the occurrence of side effects caused by conventional medication for prolonged employment, dermatologists and patients show solicitude for multifaceted effective methods to control the chronic and relapsing nature of neurodermatitis.
Although new modalities are continuously coming up for pruritus, there remains a great gap for providing symptom relief.
Furthermore, there is a lack in the quantitative knowledge and information in the published studies about benefits of shockwave therapy on the treatment of pruritus in neurodermatitis patients. So, this study is designed to outline the therapeutic efficacy of shockwave therapy on the treatment of pruritus in neurodermatitis patients.
- Conditions
- Neurodermatitis
- Being tested
- Shockwave therapy, Emollients & corticosteroids
- Medical subject headings
- Neurodermatitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Shockwave therapyDevice
The procedures for Extracorporeal Shockwave Therapy (ESWT) involve several steps. First, the patient is positioned comfortably, and the physiotherapist explains the treatment procedure. Before the session begins, the device cables are checked for proper functioning. The shockwave type used is Non-Focused/Radial, with a treatment duration not exceeding 10 minutes. The frequency is set at 4 Hz, and the intensity ranges from 0.05 to 0.20 mJ/mm². Each session involves a total of 1000 to 2000 shocks. The treatment consists of four sessions, each held once a week.
Emollients & corticosteroidsDrug
Patients in both groups will receive emollients \& corticosteroids for one month.
| Study group | Role | What they receive |
|---|---|---|
| Shockwave therapy + corticosteroids + emollients | Experimental | It will include 17 patients suffering from neurodermatitis who will receive shockwave therapy for 10min, 4 sessions, once per week and emollients \& corticosteroids for a month. Receives: Device: Shockwave therapy; Drug: Emollients & corticosteroids |
| Corticosteroids & Emollients | Active comparator | It will include 17 patients suffering from neurodermatitis who will receive their emollients \& corticosteroids only for a month. Receives: Drug: Emollients & corticosteroids |
What is being measured
The primary outcome is the main question the study is designed to answer.
5-D Itching Scale
The 5-D Itching Scale will be used to assess the improvement of cases by evaluating pruritus severity. Patients will complete the scale both before starting the treatment and at four sessions following the treatment. The following steps will be followed during the assessment: the patient will be positioned comfortably (sitting position), the physiotherapist will explain the pruritus symptoms score to the patient, and the patient will determine their points on the 5-D itch scale.
Measured: one month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Oct 2025
- Study start15 Dec 2024
- Primary completion15 Sep 2025
- Study completion25 Oct 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for NeurodermatitisStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 34 participants (actual)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Abd Al Rahman Khaled Muhammed Muhammed, Cairo University
- Investigators
- Nessrien Afify Abd El Rashid, PhD, Study chair, Assistant Professor, Cairo UniversityNoha Zakaria Tawfik, PhD, Study director, Assistant Professor, Suez Canal UniversityDoaa Atef Aly, PhD, Study director, Lecturer, Cairo university
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07206680
- Sponsor's protocol ID
- P.T.REC/012/005978
- Status last verified
- Sep 2025
- First submitted
- 26 Sep 2025
- Last updated
- 9 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Extracorporeal Shockwave Therapy on Pruritus in Neurodermatitis Patients
- ClinicalTrials.gov ID
- NCT07206680
- Acronym / sponsor ID
- P.T.REC/012/005978
- Conditions
- Neurodermatitis
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 34 participants (actual)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- 15 Dec 2024 (actual)
- Primary completion
- 15 Sep 2025 (actual)
- Study completion
- 25 Oct 2025 (actual)
- First posted
- 3 Oct 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the therapeutic effect of shockwave therapy on reducing pruritus in neurodermatitis patients.
Detailed description
Based on the occurrence of side effects caused by conventional medication for prolonged employment, dermatologists and patients show solicitude for multifaceted effective methods to control the chronic and relapsing nature of neurodermatitis.
Although new modalities are continuously coming up for pruritus, there remains a great gap for providing symptom relief.
Furthermore, there is a lack in the quantitative knowledge and information in the published studies about benefits of shockwave therapy on the treatment of pruritus in neurodermatitis patients. So, this study is designed to outline the therapeutic efficacy of shockwave therapy on the treatment of pruritus in neurodermatitis patients.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Shockwave therapy + corticosteroids + emollients | Experimental | Device: Shockwave therapy, Drug: Emollients & corticosteroidsIt will include 17 patients suffering from neurodermatitis who will receive shockwave therapy for 10min, 4 sessions, once per week and emollients \& corticosteroids for a month. |
| Corticosteroids & Emollients | Active comparator | Drug: Emollients & corticosteroidsIt will include 17 patients suffering from neurodermatitis who will receive their emollients \& corticosteroids only for a month. |
Who may qualify
- Ages
- 55 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Age range between 55:75 years.
- Male and female patients will participate in the study.
- All patients have neurodermatitis.
- All patients will be received the same approach of medication and nursing care.
- All patients enrolled in the study will have their informed consent.
Key exclusion criteria (7 listed)
- Patients diagnosed with cancer.
- Pregnant woman.
- active infection.
- Patients with any systemic diseases that may interfere with the objectives of the study.
- Cardiac pacemakers or other implantable devices.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Shockwave therapyThe procedures for Extracorporeal Shockwave Therapy (ESWT) involve several steps. First, the patient is positioned comfortably, and the physiotherapist explains the treatment procedure. Before the session begins, the device cables are checked for proper functioning. The shockwave type used is Non-Focused/Radial, with a treatment duration not exceeding 10 minutes. The frequency is set at 4 Hz, and the intensity ranges from 0.05 to 0.20 mJ/mm². Each session involves a total of 1000 to 2000 shocks. The treatment consists of four sessions, each held once a week. | Device | Shockwave therapy + corticosteroids + emollients |
| Emollients & corticosteroidsPatients in both groups will receive emollients \& corticosteroids for one month. | Drug | Corticosteroids & Emollients, Shockwave therapy + corticosteroids + emollients |
Primary outcome
5-D Itching Scale
Time frame: one month
The 5-D Itching Scale will be used to assess the improvement of cases by evaluating pruritus severity. Patients will complete the scale both before starting the treatment and at four sessions following the treatment. The following steps will be followed during the assessment: the patient will be positioned comfortably (sitting position), the physiotherapist will explain the pruritus symptoms score to the patient, and the patient will determine their points on the 5-D itch scale.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Mar 2026.
Related trials for Neurodermatitis
RecruitingPhase 1
A Phase I Clinical Trial to Evaluate the Single Dose Ascending and Food Effects of PG-033 in Healthy Adults
Lichen Simplex Chronicus
Not yet recruitingPhase 1
A Study to Evaluate the Multiple Dose Ascending of PG-033 in Healthy Adult Participants.
Lichen Simplex Chronicus
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nessrien Afify Abd El Rashid, PhD study chair
Assistant Professor, Cairo University
Noha Zakaria Tawfik, PhD study director
Assistant Professor, Suez Canal University
Doaa Atef Aly, PhD study director
Lecturer, Cairo university
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Shockwave therapy and Emollients & corticosteroids in people with Neurodermatitis, run by Cairo University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
5-D Itching Scale (time frame: one month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Mar 2026.